Coston McIsaac & Partners’s Idexx Laboratories IDXX Stock Holding History

Coston McIsaac & Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19K	Buy	34 +1	+3%	+$641	﹤0.01%	473
2025 Q4	$22K	Buy	33 +1	+3%	+$681	0.01%	447
2025 Q3	$20K	Hold	32	–	–	﹤0.01%	446
2025 Q2	$17K	Hold	32	–	–	﹤0.01%	453
2025 Q1	$13K	Buy	32 +1	+3%	+$434	﹤0.01%	463
2024 Q4	$12K	Hold	31	–	–	﹤0.01%	461
2024 Q3	$15	Hold	31	–	–	﹤0.01%	439
2024 Q2	$15K	Hold	31	–	–	﹤0.01%	417
2024 Q1	$16K	Hold	31	–	–	0.01%	411
2023 Q4	$17K	Hold	31	–	–	0.01%	403
2023 Q3	$13K	Buy	31 +30	+3,000%	+$15K	﹤0.01%	442
2023 Q2	$0	Buy	+1	New	+$479	﹤0.01%	796

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coston McIsaac & Partners's IDXX Position: Q1 2026 in Review

Coston McIsaac & Partners increased its Idexx Laboratories (IDXX) stake by 3% in Q1 2026, buying an estimated $641 and bringing the position to 34 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #473.

Coston McIsaac & Partners first reported a position in IDXX in Q2 2023 and has held it in 12 quarters since. The position peaked at $22K in Q4 2025. 1,312 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Coston McIsaac & Partners held 34 shares of Idexx Laboratories worth $19K as of Q1 2026.
Coston McIsaac & Partners bought 1 Idexx Laboratories share in Q1 2026, an estimated $641.
Idexx Laboratories made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q1 2026, its #473 holding.
Coston McIsaac & Partners first reported a position in Idexx Laboratories in Q2 2023 and has held it in 12 quarters since.
Coston McIsaac & Partners's Idexx Laboratories position peaked at $22K in Q4 2025.
1,312 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Coston McIsaac & Partners's 13F filing for Q1 2026, filed 22 Apr 2026.